Parallax Volatility Advisers’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-16,650
| Closed | -$2.33M | – | 1596 |
|
|
2025
Q2 | $2.33M | Sell |
16,650
-178,800
| -91% | -$25.1M | 0.01% | 834 |
|
|
2025
Q1 | $28.7M | Buy |
195,450
+50,950
| +35% | +$7.37M | 0.08% | 209 |
|
|
2024
Q4 | $18.9M | Sell |
144,500
-209,250
| -59% | -$29.3M | 0.04% | 360 |
|
|
2024
Q3 | $55.1M | Buy |
353,750
+277,800
| +366% | +$44.8M | 0.1% | 155 |
|
|
2024
Q2 | $11.8M | Sell |
75,950
-219,150
| -74% | -$33M | 0.03% | 426 |
|
|
2024
Q1 | $40M | Buy |
295,100
+49,950
| +20% | +$6.61M | 0.09% | 188 |
|
|
2023
Q4 | $33M | Buy |
245,150
+177,150
| +261% | +$23M | 0.07% | 265 |
|
|
2023
Q3 | $9.21M | Buy |
68,000
+38,700
| +132% | +$5.29M | 0.02% | 566 |
|
|
2023
Q2 | $4.19M | Sell |
29,300
-4,850
| -14% | -$714K | 0.01% | 856 |
|
|
2023
Q1 | $4.74M | Sell |
34,150
-3,850
| -10% | -$518K | 0.01% | 888 |
|
|
2022
Q4 | $5.15M | Sell |
38,000
-64,400
| -63% | -$8.08M | 0.01% | 1015 |
|
|
2022
Q3 | $11.2M | Buy |
102,400
+57,950
| +130% | +$7.35M | 0.02% | 729 |
|
|
2022
Q2 | $5.87M | Buy |
44,450
+10,550
| +31% | +$1.38M | 0.01% | 919 |
|
|
2022
Q1 | $4.5M | Buy |
+33,900
| New | +$4.07M | ﹤0.01% | 1029 |
|
|
2020
Q4 | – | Sell |
-51,300
| Closed | -$5.62M | – | 2395 |
|
|
2020
Q3 | $5.62M | Sell |
51,300
-187,700
| -79% | -$20.9M | ﹤0.01% | 1256 |
|
|
2020
Q2 | $25.3M | Buy |
+239,000
| New | +$24.7M | 0.03% | 445 |
|
|
2019
Q2 | – | Sell |
-500
| Closed | -$40K | – | 2556 |
|
|
2019
Q1 | $40K | Buy |
+500
| New | +$39.4K | ﹤0.01% | 2403 |
|
|
2018
Q4 | – | Sell |
-11,050
| Closed | -$874K | – | 2906 |
|
|
2018
Q3 | $874K | Sell |
11,050
-15,200
| -58% | -$1.15M | ﹤0.01% | 1312 |
|
|
2018
Q2 | $1.84M | Buy |
26,250
+17,250
| +192% | +$1.24M | ﹤0.01% | 934 |
|
|
2018
Q1 | $629K | Sell |
9,000
-140,000
| -94% | -$9.7M | ﹤0.01% | 1066 |
|
|
2017
Q4 | $10.3M | Buy |
149,000
+3,950
| +3% | +$266K | 0.01% | 402 |
|
|
2017
Q3 | $9.83M | Sell |
145,050
-193,700
| -57% | -$12.2M | 0.02% | 411 |
|
|
2017
Q2 | $23.1M | Sell |
338,750
-444,950
| -57% | -$29.1M | 0.04% | 229 |
|
|
2017
Q1 | $48.8M | Buy |
+783,700
| New | +$45.6M | 0.1% | 128 |
|
|
2016
Q4 | – | Sell |
-131,350
| Closed | -$8.63M | – | 3037 |
|
|
2016
Q3 | $8.63M | Buy |
131,350
+50,950
| +63% | +$3.33M | 0.02% | 490 |
|
|
2016
Q2 | $4.86M | Buy |
80,400
+60,300
| +300% | +$3.5M | 0.01% | 627 |
|
|
2016
Q1 | $1.13M | Buy |
+20,100
| New | +$1.21M | ﹤0.01% | 1138 |
|
|
2015
Q3 | – | Sell |
-40,000
| Closed | -$2.55M | – | 2847 |
|
|
2015
Q2 | $2.55M | Buy |
+40,000
| New | +$2.74M | 0.01% | 984 |
|
Other funds holding AZN
IA
VCM
VAM
Parallax Volatility Advisers's AZN Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 63,249 shares — an estimated $11.6M sold.
Parallax Volatility Advisers first reported a position in AZN in Q4 2015 and held it in 23 quarters. The position peaked at $11.6M in Q4 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Parallax Volatility Advisers reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 63,249 AstraZeneca shares in Q1 2026, an estimated $11.6M.
- Parallax Volatility Advisers first reported a position in AstraZeneca in Q4 2015 and held it in 23 quarters.
- Parallax Volatility Advisers's AstraZeneca position peaked at $11.6M in Q4 2025.
- 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.